EBLN1 Inhibitors
EBLN1 inhibitors are a category of chemical compounds specifically designed to impede the activity of the EBLN1 protein, which is encoded by the gene EBLN1. The EBLN1 protein plays a crucial role in a particular signaling pathway; thus, the inhibitors are tailored to disrupt this pathway to decrease the protein's functional activity. These inhibitors work by directly binding to EBLN1 or by altering the protein's conformation, thereby preventing it from participating in its normal biological activities. The exact mechanism of action for each EBLN1 inhibitor can vary, but the commonality lies in their ability to prevent the EBLN1 protein from carrying out its role in the signaling process.
The specificity of EBLN1 inhibitors is a key aspect of their function. By targeting the specific interactions and processes that involve EBLN1, these inhibitors can effectively reduce the activity of the protein without affecting unrelated pathways. This level of specificity is achieved through the careful design of the inhibitor molecules, which often involves an in-depth understanding of the protein's structure and the molecular dynamics of its interactions. The inhibitors may block the active site of EBLN1 or might interfere with its ability to bind to other molecules that are essential for its function. By hindering EBLN1's activity, these inhibitors can indirectly affect various cellular processes that depend on the proper functioning of this protein. The overall impact of EBLN1 inhibitors is a decrease in the biological processes that the EBLN1 protein facilitates.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent non-selective inhibitor of protein kinases. It can inhibit the kinase activity of EBLN1 by competing with ATP binding sites, thus reducing EBLN1's phosphorylation capability and downstream signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a selective inhibitor of PI3K, which is upstream of many signaling pathways including ones that may involve EBLN1. By inhibiting PI3K, LY294002 can reduce the activation of AKT and other downstream targets, potentially diminishing EBLN1's activity if it is associated with this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a key regulator of cell growth and proliferation. If EBLN1 is involved in mTOR signaling, rapamycin could indirectly reduce EBLN1's functional activity by disrupting this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which functions upstream in the MAPK pathway. If EBLN1's activity is related to the MAPK pathway, inhibition of MEK could lead to decreased activation of EBLN1. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. By inhibiting p38 MAPK, it could impede the activation of downstream proteins that EBLN1 may interact with or regulate, thereby reducing its functional activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor that acts by covalently binding to the catalytic site of the enzyme. Similar to LY294002, if EBLN1 is part of a PI3K-dependent pathway, its activity would be indirectly diminished. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, preventing the activation of ERK1/2 in the MAPK pathway. If EBLN1 is modulated by ERK activity, U0126 would result in reduced functional activity of EBLN1. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which can regulate apoptosis and other cellular functions. Inhibition of JNK could decrease EBLN1 functional activity if it is associated with JNK signaling. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine specifically inhibits the activation of AKT. If EBLN1 functions in concert with or is regulated by AKT signaling, then its activity would be indirectly decreased by triciribine. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Cyclosporin A inhibits calcineurin, thereby affecting T-cell activation and other signaling events. If EBLN1 is implicated in calcineurin-mediated pathways, its activity would be indirectly inhibited. | ||||||